Deslypere J P
Department of Endocrinology, Internal Medicine, University Hospital of Ghent, Belgium.
Acta Cardiol. 1989;44(5):379-88.
In a 6-week multicenter study, we compared the efficacy and tolerance of a treatment with 10 mg of simvastatin, a new inhibitor of the HMG-CoA reductase to that of 12 g cholestyramine in 145 patients whose total cholesterol remained between 250 and 350 mg/dl after 4 weeks of a standard lipid-lowering diet. The decrease in total cholesterol reached 21% in the simvastatin group and 16% in the cholestyramine group (p less than 0.01) while the LDL-cholesterol decreased respectively by 30% and 25%. HDL cholesterol increased by 11% in the simvastatin group and by 7% in the cholestyramine group. The ratios of total to HDL cholesterol and LDL to HDL cholesterol decreased by 28.1% and 35.8% respectively with simvastatin and by only 19.5% and 27.9% respectively with cholestyramine. Triglycerides decreased by 5.8% with simvastatin and increased by 8.5% with cholestyramine. Significantly less adverse experiences were observed with simvastatin than with cholestyramine. Simvastatin at the dosage of 10 mg appeared to be at least as efficient as 12 g of cholestyramine and generally better tolerated.
在一项为期6周的多中心研究中，我们比较了10毫克辛伐他汀（一种新型HMG-CoA还原酶抑制剂）与12克考来烯胺对145例患者的疗效和耐受性。这些患者在接受4周标准降脂饮食后，总胆固醇水平仍维持在250至350毫克/分升之间。辛伐他汀组的总胆固醇下降了21%，考来烯胺组下降了16%（p小于0.01），而低密度脂蛋白胆固醇分别下降了30%和25%。辛伐他汀组的高密度脂蛋白胆固醇升高了11%，考来烯胺组升高了7%。辛伐他汀使总胆固醇与高密度脂蛋白胆固醇的比值以及低密度脂蛋白与高密度脂蛋白胆固醇的比值分别下降了28.1%和35.8%，而考来烯胺仅分别下降了19.5%和27.9%。辛伐他汀使甘油三酯下降了5.8%，考来烯胺则使其升高了8.5%。与考来烯胺相比，辛伐他汀的不良事件明显更少。10毫克剂量的辛伐他汀似乎至少与12克考来烯胺一样有效，且总体耐受性更好。
